On July 27, Daishin Securities stated that while short-term earnings are important, more attention should be paid to the new drug development strategy of Samsung Epis Holdings. The target price was revised down from 620,000 won to 560,000 won, reflecting changes in profit estimates, but the investment rating was maintained at 'Buy'.


Ga-Hye Hong, an analyst at Daishin Securities, said, "We have lowered the target price by 9.6% to reflect adjustments in profit forecasts due to increased research and development (R&D) investment," adding, "However, the current share price does not reflect the value of new drugs or the platform premium. If the results of the open innovation strategy become more visible, there is potential for a valuation re-rating."


For the second quarter of this year, Samsung Epis Holdings posted consolidated sales of 391.9 billion won and operating profit of 58.8 billion won. Analyst Hong noted, "The consolidated operating profit includes 24.9 billion won in non-cash accounting adjustments, such as amortization of purchase price allocation (PPA) for development expenses and unrealized inventory gains." She added, "The key subsidiary, Samsung Bioepis, recorded sales of 392.2 billion won, down 2% year-on-year, and operating profit of 86.6 billion won, down 4% from the same period last year." She continued, "Sales temporarily decreased due to adjustments in the product supply schedule, but with normalization of supply in the second half, we are maintaining annual sales growth guidance of 10%."


The biosimilar business is also evaluated to be progressing smoothly. Analyst Hong explained, "The biosimilar SB15 for ophthalmic diseases began direct sales in the European Union (EU) in June, and SB17 for autoimmune diseases has been launched in Japan and has signed licensing agreements for Canada and Australia, marking ongoing expansion of both product range and geographic coverage." She further stated, "On the development side, the anticancer biosimilar SB27, referencing 'Keytruda,' demonstrated equivalent pharmacokinetics (PK) and objective response rates (ORR) in interim analyses of global Phase 1 and Phase 3 clinical trials, increasing the likelihood of clinical completion within this year."



She argued that the focus should be on the materialization of the open innovation strategy, rather than short-term results. Analyst Hong said, "Because consolidated profits will, for the time being, be influenced by non-cash factors such as PPA amortization and inventory unrealized gains reversals, it is important to pay attention to the main business results of Epis, the direction of new drug development, and, above all, the materialization of the open innovation strategy that became evident this quarter, rather than fluctuations in short-term performance." She added, "It is positive that the company is expanding from a focus primarily on biosimilars to a new drug development strategy that actively pursues external technology acquisition. If the visibility of new drug development results increases, it could lead to a reevaluation of the company's valuation."

[Click e-Stock] "Samsung Epis Holdings: Focus on New Drug Development Strategy Over Short-Term Earnings... Target Price Lowered" View original image


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing